Clinical Pharmacogenetics of Irinotecan (CPT-11)

References

• Akaba, K., Kimura, T., Sasaki, A., Tanabe, S., Ikegami, T., Hashimoto, M., Umeda, H., Yoshida, H., Umetsu, K., Chiba, H., Yuasa, I., Hayasaka, K. (1998). Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46:21–26. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ando, Y., Figg, W. D. (2002). Irinotecan in small-cell lung cancer. N. Engl. J. Med. 346:1414–1415. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., Kamataki, T. (1998a). UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. 9:845–847. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ando, Y., Chida, M., Nakayama, K., Saka, H., Kamataki, T. (1998b). The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 8:357–360. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., Hasegawa, Y. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:6921–6926. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ando, Y., Ueoka, H., Sugiyama, T., Ichiki, M., Shimokata, K., Hasegawa, Y. (2002a). Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther. Drug Monit. 24:111–116. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ando, M., Ando, Y., Sekido, Y., Ando, M., Shimokata, K., Hasegawa, Y. (2002b) Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn. J. Cancer Res. 93:591–597., [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Beutler, E., Gelbart, T., Demina, A. (1998). Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. U. S. A. 95:8170–8174. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bosma, P. J., Roy Chowdhury, J., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Oude Elferink, R. P. J., Roy Chowdhury, N. (1995). The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333:1171–1175. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J. M., Mahjoubi, M., Hérait, P., Armand, J. P., Bugat, R., Clavel, M., Marty, M. E. (1995). Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 6:141–151. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• de Jonge, M. J. A., Verweij, J., de Bruijn, P., Brouwer, E., Mathijssen, R. H., van Alphen, R. J., de Boer-Dennert, M. M., Vernillet, L., Jacques, C., Sparreboom, A. (2000). Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J. Clin. Oncol. 18:195–203. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• de Jong, F. A., Marsh, S., Mathijssen, R. H., King, C., Verweij, J., Sparreboom, A., McLeod, H. L. (2004). ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10:5889–5894. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., Cloughsey, T., Stewart, E. S., Colvin, O. M., Provenzale, J. M., McLendon, R. E., Bigner, D. D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring, G. L., Miller, L. L. (1999). Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17:1516–1525. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gagné, J. F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., Guillemette, C. (2002). Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62:608–617. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gong, Q. H., Cho, J. W., Huang, T., Potter, C., Gholami, N., Basu, N. K., Kubota, S., Carvalho, S., Pennington, M. W., Owens, I. S., Popescu, N. C. (2001). Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357–368. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hasegawa, Y., Sarashina, T., Ando, M., Kitagawa, C., Mori, A., Yoneyama, M., Ando, Y., Shimokata, K. (2004). Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem. 50:1479–1480. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramirez, J., Rudin, C. M., Vokes, E. E., Ratain, M. J. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22:1382–1388. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Isselbacher, K. J. (1997). Bilirubin metabolism and hyperbilirubinemia. In: Fauci, A. S., Braunwald, E., Isselbacher, K. J., Wilson, J. D., Martin, J. B., Kasper, D. L., Hauser, S. L., Long, D. L. eds. Harrision's Principles of Internal Medicine 14th ed. New York: McGraw-Hill, 1672–1677.
   Google Scholar
• Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., Ratain, M. J. (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101:847–854. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Iyer, L., Hall, D., Das, S., Mortell, M. A., Ramírez, J., Kim, S., Di Rienzo, A., Ratain, M. J. (1999). Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65:576–582. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Iyer, L., Das, S., Janisch, L., Wen, M., Ramirez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., Ratain, M. J. (2002). UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:43–47. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Japan Society for Cancer Therapy. (1993). Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J. Jpn. Soc. Cancer Ther. 28:101–130. [CSA]
   Google Scholar
• Kitagawa, C., Ando, M., Ando, Y., Sekido, Y., Usui, M., Takahashi, K., Shimokata, K., Hasegawa, Y. (2004). Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and irinotecan toxicity. J. Clin. Oncol. 22:129. (suppl.; abstr. 2009). [CSA]
   Web of Science ®Google Scholar
• Kitagawa, C., Ando, M., Ando, Y., Sekido, Y., Wakai, K., Imaizumi, K., Shimokata, K., Hasegawa, Y. (2005). Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenetics (in press). [CSA]
   Google Scholar
• Kubota, K., Nishiwaki, Y., Ohashi, Y., Saijo, N., Ohe, Y., Tamura, T., Negoro, S., Ariyoshi, Y., Nakagawa, K., Fukuoka, M. (2004). The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 22:618. (suppl.; abstr. 7006). [CSA]
   Google Scholar
• Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Bélanger, A., Fournel-Gigleux, S., Green, M., Hum, D. W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Roy Chowdhury, J., Ritter, J. K., Schachter, H., Tephly, T. R., Tipton, K. E., Nebert, D. W. (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255–269. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., Baiget, M. (2004). UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91:678–682. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., Sparreboom, A. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182–2194. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mathijssen, R. H., Verweij, J., de Bruijn, P., Loos, W. J., Sparreboom, A. (2002). Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst. 94:1247–1249. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mathijssen, R. H., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., McLeod, H. L. (2003). Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9:3246–3253. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mathijssen, R. H., de Jong, F. A., van Schaik, R. H., Lepper, E. R., Friberg, L. E., Rietveld, T., de Bruijn, P., Graveland, W. J., Figg, W. D., Verweij, J., Sparreboom, A. (2004). Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl. Cancer Inst. 96:1585–1592. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Meyerhardt, J. A., Kwok, A., Ratain, M. J., McGovren, J. P., Fuchs, C. S. (2004). Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 22:1439–1446. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monaghan, G., Ryan, M., Seddon, R., Hume, R., Burchell, B. (1996). Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578–581. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., Taguchi, T. (1991). Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 83:1164–1168. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H. (1992). Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84:972–974. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Paoluzzi, L., Singh, A. S., Price, D. K., Danesi, R., Mathijssen, R. H., Verweij, J., Figg, W. D., Sparreboom, A. (2004). Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol. 44:854–860. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Cosmetics Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare. (1996). Summary Basis of Approval (SBA) No.1 (Revised Edition): Irinotecan Hydrochloride. Tokyo: Yakuji Nippo, Ltd..
   Google Scholar
• Pitot, H. C., Goldberg, R. M., Reid, J. M., Sloan, J. A., Skaff, P. A., Erlichman, C., Rubin, J., Burch, P. A., Adjei, A. A., Alberts, S. A., Schaaf, L. J., Elfring, G., Miller, L. L. (2000). Phases I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin. Cancer Res. 6:2236–2244. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ritter, J. K., Chen, F., Sheen, Y. Y., Tran, H. M., Kimura, S., Yeatman, M. T., Owens, I. S. (1992). A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem. 267:3257–3261. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J. P., Robert, J. (1997). Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res. 3:1261–1266. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Roses, A. D. (2000). Pharmacogenetics and the practice of medicine. Nature 405:857–865. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rouits, E., Boisdron-Celle, M., Dumont, A., Guerin, O., Morel, A., Gamelin, E. (2004). Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10:5151–5159. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sai, K., Saeki, M., Saito, Y., Ozawa, S., Katori, N., Jinno, H., Hasegawa, R., Kaniwa, N., Sawada, J., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kitamura, Y., Kamatani, N., Minami, H., Ohtsu, A., Shirao, K., Yoshida, T., Saijo, N. (2004). UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75:501–515. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Senafi, S. B., Clarke, D. J., Burchell, B. (1994). Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J. 303:233–240. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sugatani, J., Yamakawa, K., Yoshinari, K., Machida, T., Takagi, H., Mori, M., Kakizaki, S., Sueyoshi, T., Negishi, M., Miwa, M. (2002). Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 292:492–497. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tadokoro, J., Hasegawa, H., Hayakawa, K., Takahashi, M., Nakata, H., Terada, K., Sakata, Y., Fukuoka, M. (2002). Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients. Proc. Am. Soc. Clin. Oncol. 21:259. (suppl.; abstr. 1033). [CSA]
   Google Scholar
• Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., Cvitkovic, E. (1997). Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol. 8:1049–1051. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Xie, R., Mathijssen, R. H. J., Sparreboom, A., Verweij, J., Karlsson, M. O. (2002). Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin. Pharmacol. Ther. 72:265–275. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar